Powered by RND
PodcastsVidenskabBetween the Biotech Waves
Lyt til Between the Biotech Waves i appen
Lyt til Between the Biotech Waves i appen
(2.537)(250.190)
Gem station
Vækkeur
Sleeptimer

Between the Biotech Waves

Podcast Between the Biotech Waves
Nessan Bermingham PhD
Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.

Tilgængelige episoder

5 af 36
  • A Between the Biotech Waves Conversation with Peter Barrett
    Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Barrett.Peter is a partner at Atlas Venture, where he has been a key player in the creation of numerous novel therapeutic and drug discovery platform companies. With an unyielding passion for advancing healthcare, Peter has been directly involved in co-founding, building, investing and supporting numerous companies including Celera Genomics, Alynlam Therapeutics and Momenta, to name just a few.Known for his entrepreneurial spirit, Peter co-founded Celera Genomics, where he led groundbreaking work that culminated in the first successful sequencing of the human genome in 2001. His strategic insights propelled Celera into the public arena, and his leadership has shaped the trajectory of many biotech companies over the years.In addition to his roles in the biotech sector, Peter is an Executive Fellow at Harvard Business School and serves as the faculty chair of the advisory board for the prestigious Blavatnik Fellowship Program, helping to cultivate the next generation of leaders in science and business.Join me as we engage in a fascinating conversation with Peter Barrett, delving into his remarkable journey, the evolution of biotechnology, and the innovative spirit that drives his work.
    --------  
    53:51
  • S2 Episode 1: A conversation with Matt Porteus
    Now that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting!Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the remarkable individuals driving innovation. I’m your host, Nessan Bermingham, and today, we are honored to have Dr. Matt Porteus with us, a true pioneer in the field of genome editing.Dr. Porteus is making headlines for his role in the development of Lyfgenia, the groundbreaking CRISPR-Cas9 gene editing drug from Vertex Pharmaceuticals and CRISPR Therapeutics, designed to treat sickle cell disease. He recently founded Kamau Therapeutics, a company I am involved with, to develop a next gen curative therapy for sickle cell disease. Raised in California, Matt's academic journey began at Harvard University, where he graduated Magna Cum Laude with a focus on the ethics of recombinant DNA technology—a testament to his deep understanding of the intersection between science and society.He later completed his combined MD and PhD at Stanford Medical School, focusing on mammalian fore brain development. His postdoctoral research under Dr. David Baltimore at MIT and CalTech solidified his path toward developing innovative therapies using homologous recombination for genetic disorders, particularly in children.Returning to Stanford in 2010 as an Associate Professor, Dr. Porteus has led the way in demonstrating efficient gene correction in human cells, paving a path for curative treatments in pediatrics. His expertise extends beyond genetic diseases to include the dynamics of various pediatric conditions, with a hands-on role at the Lucille Packard Children’s Hospital, where he cares for young patients undergoing hematopoietic stem cell transplantation.Currently Matt is Sutardja Chuk professor of definitive and curative medicine.In today's episode, we’ll dive into Dr. Porteus's inspiring journey, the significance of Lyfgenia, and his vision for the future of gene editing in transforming the treatment of sickle cell disease and beyond.
    --------  
    54:32
  • Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis
    Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of work within eGenesis to develop porcine donors for human tissue transplant.Mike has a 25 year plus history in biotech from Infinity to Cadent where he played a critical role in the merger of Ataxion Therapeutics with Luc to Catabasis where he led product development and regulatory affairs to his current role as CEO and President at eGenesis. Mike earned his Ph.D. in Cell and Molecular Biology from the State University of New York Upstate Medical University.His story is fascinating. Please join me in welcoming Mike Curtis.
    --------  
    1:05:29
  • Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics
    Today I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS.Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pharmaceuticals following his multiple roles at Pfizer which included head of development and operations, European Union. He was the founding chair of Medcity and is an honorary visiting professor of molecular and clinical cancer medicine at the University of Liverpool, to name just a few roles he has had. Eliot is a member of the board of directors of Immatics and is chair of the boards of Ochre Biosciences and Avacta.
    --------  
    1:04:37
  • Episode 32: The Triplet Therapeutics story, from concept to birth, life & death.
    Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building the company and what ultimately led to it's demise. 
    --------  
    1:45:49

Flere Videnskab podcasts

Om Between the Biotech Waves

Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.
Podcast-websted

Lyt til Between the Biotech Waves, Verden forsøgt forklaret og mange andre podcasts fra hele verden med radio.dk-appen

Hent den gratis radio.dk-app

  • Bogmærke stationer og podcasts
  • Stream via Wi-Fi eller Bluetooth
  • Understøtter Carplay & Android Auto
  • Mange andre app-funktioner
Juridiske forhold
Social
v7.7.0 | © 2007-2025 radio.de GmbH
Generated: 2/15/2025 - 3:47:50 AM